尿激酶治疗急性脑梗塞的临床及血浆纤溶效果观察  

Clinical study and fibrinolytic effect in cerebral infarction with Urokinase treatment.

作　　者：杜秦川[1,2] 马瑞莲[1,2] 郭菊英[1,2] 

机构地区：[1]宁夏银川市第一人民医院神经内科 [2]甘肃省人民医院神经内科

出　　处：《临床内科杂志》1999年第1期25-26,共2页Journal of Clinical Internal Medicine

摘　　要：目的观察尿激酶（ＵＫ）治疗急性脑梗塞的临床及血浆纤溶效果的变化。方法对起病＜６小时，或起病超过６小时、但小于１２小时，ＣＴ证实的２０例脑梗塞患者静推ＵＫ３０万单位，静滴ＵＫ５０万单位，总量＜２００万单位；对治疗前后患者的神经功能缺损进行评定，并检测血浆Ｄ－二聚体和纤溶酶活性的水平。结果治疗后患者的临床症状明显改善，血浆Ｄ－二聚体及纤溶酶活性明显升高（Ｐ＜０．０１或Ｐ＜０．００１）。结论ＵＫ溶栓治疗急性脑梗塞疗效高且安全。Objective To observe the clinical and fibrinolytic effect of Urokinase(UK)therapy in the acute cerebral infarction,and alteration of Ddimer concentrations and plasmin activity. MethodsBZ20 cases suffered from cerebral infarction by CT scan,<6 hours or >6 hours and <12 hours after the onset of ischemic stroke,using UK by 300 thousand unit intravenously and 500 thousand unit intravenous injection.Total dosage is <2000 thousand unit. After treatment,the scale of neurological deficit was used for functional assessment;Plasma fibrin Ddimer levels and plasmin activity was measured. Results Patients obtain improvement dramatically,and the Ddimer levels and activity plasmin significantly increases after UK treatment(P<0001 or P<001). Conclusion Thrombolytic therapy of using UK in the early cerebral infarction is positive effect and safety.

关 键 词：尿激酶 脑梗塞 溶栓治疗 

分 类 号：R743.330.5[医药卫生—神经病学与精神病学]